Curesponse’s ex vivo organ culture technology entitled cResponse™ was developed together with the Weizmann Institute of Science. The platform enables growing of human tumors in their native tumor microenvironment, allowing for accurate prediction of drug response. The The Curesponse laboratory is ISO 15189 approved for both genomics and functional tests. The cResponse™ treatment selection assay, has been validated on animal models of cancer (PDX). In addition, clinical validation of cResponse on different indications, testing a large variety of drugs, is ongoing at several medical centers with encouraging preliminary results.